Monday, December 18, 2006 8:30:00 AM PDT | VentureDeal Staff
CAMBRIDGE, MA -- Cequent Pharmaceuticals today announced the closing of a $6 million series A round of financing. The company licensed technology from the Beth Israel Deaconess Medical Center & Harvard Medical School which allows for RNAi-based treatments to be carried by bacteria into targeted areas deep within the human body, without surgery. Cequent is in pre-clinical stage and is focusing its efforts on gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
